Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens
Autore:
Klinguer, C; Beck, A; De-Lys, P; Bussat, MC; Blaecke, A; Derouet, F; Bonnefoy, JY; Nguyen, TN; Corvaia, N; Velin, D;
Indirizzi:
Bio Merieux Pierre Fabre, Ctr Immunol Pierre Fabre, St Julien En Genevois,France Bio Merieux Pierre Fabre St Julien En Genevois France n Genevois,France
Titolo Testata:
VACCINE
fascicolo: 30, volume: 19, anno: 2001,
pagine: 4236 - 4244
SICI:
0264-410X(20010720)19:30<4236:LQASAA>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
RESPIRATORY SYNCYTIAL VIRUS; G-PROTEIN FRAGMENT; G FUSION PROTEIN; PROTECTIVE IMMUNITY; COTTON RATS; HUMANS; BBG2NA; IMMUNOPATHOLOGY; IMMUNIZATION; ANTIBODIES;
Keywords:
mucosal vaccine; recombinant protein; nasal vaccine; dimethyldioctadecylamnionium bromide; respiratory syncytial virus;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Agriculture,Biology & Environmental Sciences
Life Sciences
Citazioni:
34
Recensione:
Indirizzi per estratti:
Indirizzo: Velin, D Bio Merieux Pierre Fabre, Ctr Immunol Pierre Fabre, 5 Ave Napoleon 3,BP 497, St Julien En Genevois, France Bio Merieux Pierre Fabre 5 Ave Napoleon 3,BP 497 St Julien En Genevois France
Citazione:
C. Klinguer et al., "Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens", VACCINE, 19(30), 2001, pp. 4236-4244

Abstract

Nasal administration of vaccines is an attractive approach which offers several significant advantages over traditional intramuscular vaccine delivery. These advantages include easier administration and induction of immune responses in the mucosal secretions of the body. In this study we describe anew potent nasal adjuvant, dimethyldioctadecylammonium bromide (DDA), thatinduces both mucosal and systemic immune responses when co-administered with diphtheria toxoid (DT), tetanus toxoid (TT) and BBG2Na antigens. In particular, we show that the nasal delivery of recombinant fragment (BBG2Na) ofthe G protein of respiratory syncytial virus (RSV) mixed with DDA induces both local and systemic anti-RSV immune responses and protects against viral challenge. Furthermore, we provide evidence that the DDA + BBG2Na vaccinedoes not induce lung immunopathology upon subsequent RSV challenge. (C) 2001 Elsevier Science Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/07/20 alle ore 07:30:10